Answers are grounded in this paper and cite their sources.
Background Approximately 1.5 million HIV positive individuals experience pregnancy annually. The goal of HIV treatment in pregnancy is to achieve viral suppression prior to delivery, minimizing the risk of vertical transmission. Dolutegravir (DTG) is an integrase strand inhibitor that prevents insert of HIV DNA into host cells, thus decreasing viral load. In a clinical trial conducted in conjunction with 60 pregnant women initiating anti-retroviral therapy (ART) in the third trimester, dolutegravir (DTG) achieved viral suppression approximately two months faster than the standard of care at the time (28d vs. 84d). Secondary endpoints from this study demonstrate transplacental and breastmilk transfer of dolutegravir to the infant and delayed clearance. The pharmacokinetics of dolutegravir in infancy remain uncharacterized, with important implications for the development of HIV and resistance if there is intermittent medication compliance and/or barriers to care. The development of a robust DTG breastmilk assay will allow future pharmacokinetic studies to quantify pharmacologic exposure and relate this to infant health, namely HIV transmission and development of resistance. The objective of this study was to develop and validate a rapid LC-MS/MS assay in breastmilk with a dynamic measuring range, suitable for application in pharmacology studies. Methods Breastmilk was purchased from commercial vendors and spiked with dolutegravir and an isotopically labeled internal standard. Samples were prepared by protein precipitation and injected into an LC-MS/MS system consisting of a Shimadzu LC-40, a C8 column, and a Sciex QTRAP 5500. Peaks were identified by monitoring two transitions for DTG and the presence of the internal standard. All data analysis was performed in Analyst and Excel. Results The DTG breastmilk assay has an analytical measuring range of 0.5-1,000 ng/mL with a final method time of 2.2 minutes. Breastmilk was prepared by protein precipitation with a required sample volume of 30 µL and an injection volume of 3 µL. There was no evidence of ion enhancement or suppression, nor was there any evidence of carryover or crosstalk. DTG was reliably detected across the analytical measuring range and among different lots of breastmilk. Conclusions This assay meets performance criteria put forth by the European Medical Association and the Food and Drug Administration. Upon completion of all validation experiments, this assay may be applied to assess the pharmacokinetics of DTG in mother-infant pairs.
No takes yet. Share an insight, caveat, or question.
Rackow et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: